Results of Operations and Financial Condition On August 6, 2026, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exc…

Results of Operations and Financial Condition On May 13, 2026, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exch…

Other Events. On May 13, 2026, vTv Therapeutics Inc. (the “Company”) filed a prospectus supplement with the SEC to increase the number of shares of Class A common stock offered under its previously-announced at-the-market sales program (the “ATM Program”) to the full amount provided for under the ATM program. In connection with the ATM Program, the Company is filing a legal opinion of Dechert LLP regarding the legality of the Class A common stock issuable under the ATM Program, which legal op…

Results of Operations and Financial Condition On March 10, 2026, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “E…

Entry into a Material Definitive Agreement. On January 30, 2026, vTv Therapeutics LLC (“vTv LLC” or the "Company"), a subsidiary of vTv Therapeutics Inc., entered into the Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. (“Newsoara”) (the “Second Amendment”) to amend the License Agreement previously entered into between vTv LLC and Newsoara on May 31, 2018 (the “Original Agreement”) . Although the Company had previously entered into an amendment with Newsoara to expand…

Results of Operations and Financial Condition On November 6, 2025, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (t…

Entry into a Material Definitive Agreement. Private Placement of Class A Common Shares and Pre-Funded Warrants On August 29, 2025, vTv Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) 5,243,732 units (the “Units”), each Unit comprised of (…

Results of Operations and Financial Condition On August 12, 2025, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Ex…

CFO — Michael Tung: Dr. Michael Tung was appointed as the new Executive Vice President and Chief Financial Officer.

Results of Operations and Financial Condition On May 15, 2025, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exch…

interim principal financial officer — Barry K. Brown: Mr. Barry K. Brown was appointed as the interim principal financial officer.

Results of Operations and Financial Condition On March 20, 2025, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “E…

Executive Vice President and Chief Financial Officer — Steven Tuch: Mr. Tuch resigned from his position as CFO and EVP.

Results of Operations and Financial Condition On November 12, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended September 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (…

Termination of a Material Definitive Agreement On October 22, 2024, vTv Therapeutics LLC (“vTv LLC”), a controlled subsidiary of vTv Therapeutics Inc. (the “Company”), received notice from OnKure Therapeutics, formerly Reneo Pharmaceuticals, Inc. ("OnKure"), of their intent to terminate the License Agreement between vTv LLC and Reneo Pharmaceuticals, Inc., dated December 21, 2017, as amended December 20, 2021 (the “Agreement”). Under the Agreement, the Company had granted OnKure an exclusive,…

Results of Operations and Financial Condition On August 8, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended June 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exc…

Entry into a Material Definitive Agreement. On June 26, 2024, vTv Therapeutics LLC (“vTv LLC”), a subsidiary of vTv Therapeutics Inc., entered into the Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. (“Newsoara”) (the “Second Amendment”) to amend the License Agreement previously entered into between vTv LLC and Newsoara on May 31, 2018 (the “Original Agreement”) . Under the Second Amendment, upon Newsoara's payment of the upfront fee of $20 million, the Original Licens…

Results of Operations and Financial Condition On May 9, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended March 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Excha…

Director — Anne Phillips: Anne Phillips was elected as a director and appointed to the Compensation Committee and Audit Committee.

Results of Operations and Financial Condition On March 13, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “E…

Results of Operations and Financial Condition. Preliminary Financial Results - Cash Balance as of December 31, 2023 Based upon preliminary estimates and information available to the Company, it expects to report that it had cash and cash equivalents of approximately $9.4 million as of December 31, 2023. The preliminary cash balance presented above is not a comprehensive statement of the Company’s financial position, and is subject to change following the completion of the Company’s financial…

Entry into a Material Definitive Agreement. Private Placement of Class A Common Shares and Pre-Funded Warrants On February 27, 2024, vTv Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) (i) an aggregate of 464,377 shares (the “Shares”) of…

Entry into a Material Definitive Agreement. On February 28, 2024, vTv Therapeutics Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“TD Cowen”), pursuant to which the Company may offer and sell, from time to time, through TD Cowen, as sales agent, shares of the Company’s Class A common stock, par value $0.01 per share, having an aggregate offering price of up to $50.0 million (the “ATM Offering”). Pursuant to General Instruction I.B.6 of…

Director — Jonathan Isaacsohn, Hersh Kozlov, John A. Fry, Howard L. Weiner, Keith Harris: Multiple directors resigned in connection with a Private Placement.

Other Events. On February 28, 2024, the Company issued a press release announcing the Private Placement. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.